1,055.00
-17.00
(-1.59%)
At close: January 31 at 3:30:23 PM GMT+9
Key Executives
Amounts are as of -- and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dongil Han | Chairman & CEO | -- | -- | -- |
| CheolHwan Lee | CFO & Inside Director | -- | -- | -- |
| Sung Ho Ryu | CTO & Non-Executive Director | -- | -- | -- |
| Daekyun Lee | Head of R&D Center | -- | -- | -- |
| David Lee | C.B.O. | -- | -- | -- |
Aptamer Sciences Inc.
407 Ho, Healthcare Innovation Park
172, Dolma-ro Bundang-gu
Seongnam, 13605
South Korea
- Sector:
- Healthcare
- Industry: Biotechnology
Description
Aptamer Sciences, Inc., a bio venture company, focuses on the Aptamer technology platform for the development of therapeutic and diagnostic platforms. The company's aptamer platforms include aptamer discovery, optimization, and the development of therapeutics and diagnostics. It offers AlloMAp and BiFAp platform programs for therapeutics; and diagnosis kits for lung and pancreatic cancer, as well as in-vitro diagnostic kits for the early diagnosis of lung cancer. Aptamer Sciences, Inc. was founded in 2011 and is headquartered in Seongnam, South Korea.
Corporate Governance
Aptamer Sciences Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
March 12, 2025 at 10:59 AM UTC - March 17, 2025 at 12:00 PM UTC
Aptamer Sciences Inc. Earnings Date
Recent Events
Recent Events Information Not Available